Component: (Network and Table)
Network
00400 - Statement - STATEMENTS OF CASH FLOWS
(http://www.iderapharma.com/role/StatementStatementsOfCashFlows)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0000861838 (http://www.sec.gov/CIK)
STATEMENTS OF CASH FLOWSPeriod [Axis]
2016-01-01 - 2016-12-31
2015-01-01 - 2015-12-31
2014-01-01 - 2014-12-31
STATEMENTS OF CASH FLOWS
 
 
 
Cash Flows from Operating Activities:
 
 
 
Net loss
(38,389,000) 
(48,555,000) 
(38,642,000) 
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
Loss from disposition of assets
4,000  
 
1,000  
Non-employee stock option expense
 
143,000  
24,000  
Stock-based compensation
6,847,000  
5,442,000  
4,322,000  
Issuance of common stock for services rendered
172,000  
122,000  
82,000  
Accretion of premiums and discounts on investments
566,000  
599,000  
213,000  
Depreciation and amortization expense
656,000  
488,000  
206,000  
Changes in operating assets and liabilities:
 
 
 
Prepaid expenses and other current assets
1,064,000  
(1,889,000) 
(329,000) 
Accounts payable, accrued expenses, and other liabilities
1,988,000  
(1,709,000) 
2,802,000  
Deferred revenue
(1,111,000) 
2,373,000  
 
Net cash used in operating activities
(28,203,000) 
 
(42,986,000) 
 
(31,321,000) 
 
Cash Flows from Investing Activities:
 
 
 
Purchases of available-for-sale securities
(2,946,000) 
(63,106,000) 
(23,623,000) 
Proceeds from maturity of available-for-sale securities
32,746,000  
29,420,000  
4,115,000  
Proceeds from sale of available-for-sale securities
1,974,000  
999,000  
 
Purchases of property and equipment
(408,000) 
(727,000) 
(1,093,000) 
Net cash provided by (used in) investing activities
31,366,000  
 
(33,414,000) 
 
(20,601,000) 
 
Cash Flows from Financing Activities:
 
 
 
Sale of common stock and warrants, net of issuance costs
49,014,000  
80,599,000  
37,137,000  
Proceeds from issuance of note payable
  
825,000  
Proceeds from exercise of common stock warrants and options and employee stock purchases
2,172,000  
2,546,000  
8,456,000  
Dividends paid
  
(798,000) 
Payments on note payable
(261,000) 
(120,000) 
 
Payments on capital lease
(7,000) 
(10,000) 
(5,000) 
Net cash provided by financing activities
50,918,000  
 
83,015,000  
 
45,615,000  
 
Net increase (decrease) in cash and cash equivalents
54,081,000  
 
6,615,000  
 
(6,307,000) 
 
Cash and cash equivalents, beginning of period
26,586,000  
19,971,000  
26,278,000  
Cash and cash equivalents, end of period
80,667,000  
 
26,586,000  
 
19,971,000